Impax to help Wyeth promote Pristiq; Pfizer expands discount program for uninsured;

> Impax Pharmaceuticals said it has agreed to use its neurology-focused sales force to co-promote Wyeth's antidepressant Pristiq. Release

> Pfizer's prescription-savings program, Together Rx Access, has expanded its eligibility income levels to allow nearly 90 percent of uninsured Americans to save on the medicines they need. Release

> GlaxoSmithKline has dropped the price of its human papillomavirus vaccine Cervaris by 30 percent in Singapore. Report

> A Citi Investment Research analyst upgraded shares of Eli Lilly & Co. to "Buy", saying the company will be able to launch its blood thinner Effient in the second quarter of 2009, and predicting annual sales of about $2 billion by 2015. Report

> The Indian pharma industry is now likely to clock 12 percent to 13 percent growth in 2000, rather than a previously expected 15 percent, because of the global economic meltdown, a research firm said. Report

> Chinese health authorities are investigating baby products made by Johnson & Johnson in response to a U.S. consumer group's charges, disputed by the company, that some chemicals contained in the products could cause cancer. Report

> AstraZeneca's Christiana, Delaware, site was one of four pharmaceutical plants to receive the Environmental Protection Agency's Energy Star ranking, part of a federal effort to recognize the nation's most energy-efficient businesses. Report

> Warner Chilcott said that one of its subsidiaries and Mayne Pharma have filed a second lawsuit against Impax Laboratories in an attempt to block the generics maker's version of their antibiotic drug Doryx. Release

> Cardinal Health has opened a new facility in Omaha, Nebraska, to manufacture radiopharmaceuticals, giving local doctors new diagnostic and treatment tools. Report

> A new survey of the state of Canada's biotech industry by Peter Brenders paints a bleak picture. Report

> Merck KGaA is funneling $19 million into a joint research project between one of its subsidiaries--EMD Serono--and the National Multiple Sclerosis Society to fast-track new therapies for MS. Report

> Biotech lobbyists loudly cheered a newly-introduced bill that offers 12 years of market exclusivity to branded biologics before they have to confront a generic competitor. Report

> San Bruno, CA-based Numerate has wrapped a $5.5 million Series B round to help finance its drug engineering work. Report

> Will the Wyeth buyout derail Pfizer's R&D makeover? Report

And Finally... A U.K. teen was suspended from community college for distributing Pfizer's sildenafil citrate to her fellow students. Report

Suggested Articles

Mylan and Pfizer's Upjohn have a name for their pending merger: Viatris. Heard that before? So has Mylan, which owns a subsidiary with the same name.

Intercept presented a data analysis that found treatment with Ocaliva led to "early and consistent improvements" in a range of noninvasive tests.

Days before Amarin faces a pivotal FDA vote on its Vascepa expansion, advisors are set to scrutinize the placebo used in its pivotal outcomes trial.